卡瑞利珠单抗联合化疗治疗晚期非小细胞型肺癌的效果及对肿瘤标志物和短期预后的影响  

Effect of camrelizumab combined with chemotherapy in treating advanced non-small cell lung cancer and its influence on tumor markers and short-term prognosis

作　　者：陶黎明 乐薇 TAO Liming;LE Wei(Department of Oncology,Jiujiang Third people's Hospital,Jiujiang,Jiangxi,332000,China)

机构地区：[1]九江市第三人民医院肿瘤科,江西九江332000

出　　处：《当代医学》2023年第25期16-19,共4页Contemporary Medicine

摘　　要：目的探讨卡瑞利珠单抗联合化疗治疗晚期非小细胞型肺癌(NSCLC)的效果及对肿瘤标志物、短期预后的影响。方法选取2019年12月至2020年12月于九江市第三人民医院接受治疗的66例晚期NSCLC患者作为研究对象,采用随机数字表法分为观察组与对照组,每组33例。对照组予以化疗、抗感染等治疗,观察组在对照组基础上加用卡瑞利珠单抗治疗。比较两组治疗6个月后临床疗效,治疗前后肿瘤标志物[癌胚抗原(CEA)、神经元特异烯醇化酶(NSE)、糖类抗原125(CA125)]水平、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、预后状况。结果观察组治疗总有效率为54.55%,高于对照组的27.27%,差异有统计学意义(P<0.05)。治疗6个月后,两组CEA、NSE、CA125水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗6个月后,两组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于治疗前,CD8^(+)水平低于治疗前,且观察组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。观察组生存率高于对照组,无进展生存时间长于对照组,差异有统计学意义(P<0.05)。结论卡瑞利珠单抗联合化疗治疗晚期NSCLCL患者疗效确切,可改善肿瘤标志物水平及预后,值得临床推广应用。Objective To investigate the efficacy of carrilizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on tumor markers and short-term prognosis.Methods A total of 66 patients with advanced NSCLC who received treatment in Jiujiang Third People's Hospital from December 2019 to December 2020 were selected as the study subjects,and they were divided into the observation group and control group by random number table method,with 33 cases in each group.The control group was treated with chemo-therapy and anti-infection,and the observation group was given carrilizumab on the basis of the control group,the clinical efficacy,tumor markers(serum carcinoembryonic antigen[CEA],neuron-specific enolase[NSE],carbohydrate antigen 125[CA125])and T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))before and after treatment,and the prognosis was compared after 6 months of follow-up were compared between the two groups.Results The total effective rate in the observation group was 54.55%,higher than 27.27%in the control group,the difference was statistical-ly significant(P<0.05).After 6 months of treatment,the levels of CEA,NSE and CA125 of the two groups were lower than before treatment,and observation group was lower than control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)of the two groups were higher than before treatment,and the levels of CD8^(+)were lower than before treatment,and the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and the level of CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).The survival rate in the observation group was higher than that in the con-trol group,and the progression-free survival time was longer than that in the control group,the differences were statistically significant(P<0.05).Conclusion Carrellizumab combined with

关 键 词：卡瑞利珠单抗 化疗 非小细胞肺癌 肿瘤标志物 预后 

分 类 号：R734.2[医药卫生—肿瘤]